Elite in Breast Cancer

Serafin M. Morales

Lleida, CT, ES 
Elite in Breast Cancer
Lleida, CT, ES 
OverviewLocationsClinical Research

Overview

Serafin Morales practices in Lleida, Spain. Mr. Morales is rated as an Elite expert by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Autosomal Recessive Hypotrichosis.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 43 articles and participated in 8 clinical trials in the study of Breast Cancer.

Gender
Male

Locations

Lleida, CT, Spain
Other Locations
Madrid, MD, Spain
Valencia, VC 46015, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)
HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Other
Study Phase: Not Applicable
Phase IB Clinical Trial of Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer With Hyperactivation of ERK and/or CDK4/6
Phase IB Clinical Trial of Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer With Hyperactivation of ERK and/or CDK4/6
Enrollment Status: Completed
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Binimetinib
Study Phase: Phase 1/Phase 2
A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC Patients
A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC Patients
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug
Study Drugs: Ipatasertib, Capecitabine, Eribulin, Carboplatin, Gemcitabine
Study Phase: Phase 2
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Endocrine therapy, Chemotherapy, Antibody-Drug Conjugates
Study Phase: Phase 2
Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drugs: Rogaratinib, Palbociclib, Fulvestrant
Study Phase: Phase 1
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Neratinib+Endocrine Therapy
Study Phase: Phase 2
A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor-Positive and HER2-negative Breast Cancer
A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor-Positive and HER2-negative Breast Cancer
Enrollment Status: Completed
Publish Date: April 01, 2022
Intervention Type: Drug
Study Drug: Onapristone
Study Phase: Early Phase 1
View 7 Less Clinical Trials

44 Total Publications

Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.
Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Morales's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile